MedTrace Logo

Study of the Impact of DPD Activity on the Efficacy of Capecitabine

NCT04198727 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2025-05-23

No results posted yet for this study

Summary

This study evaluates the Impact of DihydroPyrimidine Dehydrogenase (DPD) activity on the efficacy of Capecitabine in patients with metastatic breast cancer. The DPD phenotype before the initiation of treatment will be assess and then the patient will be follow up during the treatment with Capecitabine up to 24 month.

Conditions

  • Breast Neoplasm Malignant Female

Interventions

OTHER

DPD activity assessment

Phenotyping DPD with enzyme activity measure and uracil dosage

DRUG

Capecitabine

Capecitabine assignement at 1000mg per square meter twice daily, cycle of 21 days, 14 days of intake, 7 days of

Sponsors & Collaborators

  • Cerbaliance

    collaborator UNKNOWN

  • Centre Antoine Lacassagne

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-20
Primary Completion
2026-01-31
Completion
2030-07-31

Countries

  • France
  • Monaco

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04198727 on ClinicalTrials.gov